In unresectable G/GEJ adenocarcinoma, first-line treatment consists of chemotherapy plus either immunotherapy for HER2-negative CPS-PDL1-positive (≥5) tumors (5) or trastuzumab for HER2-positive disease (4). Here, CD274 is linked to gastroesophageal junction adenocarcinoma.